BHCM
HUMA icon

Brevan Howard Capital Management’s Humacyte HUMA Stock Holding History

Brevan Howard Capital Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-80,394
Closed -$140K – 2025
2025
Q3 		$140K Sell
80,394
-47,464
-37% -$93K ﹤0.01% 1828
2025
Q2 		$267K Sell
127,858
-40,737
-24% -$78.3K ﹤0.01% 1594
2025
Q1 		$287K Sell
168,595
-707,745
-81% -$2.66M ﹤0.01% 874
2024
Q4 		$4.43M Buy
876,340
+846,070
+2,795% +$4.19M 0.03% 164
2024
Q3 		$165K Buy
30,270
+11,380
+60% +$75K ﹤0.01% 1028
2024
Q2 		$90.7K Buy
+18,890
New +$98.3K ﹤0.01% 972
2024
Q1 		– Sell
-31,018
Closed -$88.1K – 1144
2023
Q4 		$88.1K Buy
+31,018
New +$79.6K ﹤0.01% 972

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Brevan Howard Capital Management's HUMA Position: Q4 2025 in Review

Brevan Howard Capital Management sold out of Humacyte (HUMA) in Q4 2025, closing a stake of 80,394 shares — an estimated $140K sold.

Brevan Howard Capital Management first reported a position in HUMA in Q4 2023 and held it in 7 quarters. The position peaked at $4.43M in Q4 2024. 147 funds tracked by Wall St. Rank hold HUMA as of Q4 2025.

  • Brevan Howard Capital Management reported no remaining Humacyte position as of Q4 2025 after selling out during the quarter.
  • Brevan Howard Capital Management sold 80,394 Humacyte shares in Q4 2025, an estimated $140K.
  • Brevan Howard Capital Management first reported a position in Humacyte in Q4 2023 and held it in 7 quarters.
  • Brevan Howard Capital Management's Humacyte position peaked at $4.43M in Q4 2024.
  • 147 funds tracked by Wall St. Rank held Humacyte as of Q4 2025.

Based on Brevan Howard Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.